Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Are Crazy About Alkermes Plc (ALKS)

Page 1 of 2

What’s a smart Alkermes Plc (NASDAQ:ALKS) investor to do?

In the financial world, there are plenty of indicators shareholders can use to watch stocks. A couple of the best are hedge fund and insider trading activity. At Insider Monkey, our research analyses have shown that, historically, those who follow the best picks of the best hedge fund managers can trounce the broader indices by a healthy margin (see just how much).

Equally as crucial, optimistic insider trading activity is a second way to analyze the marketplace. Obviously, there are plenty of motivations for a corporate insider to sell shares of his or her company, but only one, very obvious reason why they would behave bullishly. Many empirical studies have demonstrated the useful potential of this tactic if shareholders know where to look (learn more here).

Alkermes Plc (NASDAQ:ALKS)

Thus, we’re going to study the recent info surrounding Alkermes Plc (NASDAQ:ALKS).

How are hedge funds trading Alkermes Plc (NASDAQ:ALKS)?

Heading into Q3, a total of 20 of the hedge funds we track were bullish in this stock, a change of 33% from one quarter earlier. With the smart money’s positions undergoing their usual ebb and flow, there exists a few key hedge fund managers who were boosting their stakes meaningfully.

Out of the hedge funds we follow, Arthur B Cohen and Joseph Healey’s Healthcor Management LP had the largest position in Alkermes Plc (NASDAQ:ALKS), worth close to $23.7 million, accounting for 1.4% of its total 13F portfolio. Sitting at the No. 2 spot is Millennium Management, managed by Israel Englander, which held a $22.8 million position; 0.1% of its 13F portfolio is allocated to the stock. Some other hedgies that are bullish include Jim Simons’s Renaissance Technologies, Kevin Kotler’s Broadfin Capital and Brian Ashford-Russell and Tim Woolley’s Polar Capital.

As industrywide interest increased, specific money managers were leading the bulls’ herd. Healthcor Management LP, managed by Arthur B Cohen and Joseph Healey, established the most outsized position in Alkermes Plc (NASDAQ:ALKS). Healthcor Management LP had 23.7 million invested in the company at the end of the quarter. Israel Englander’s Millennium Management also initiated a $22.8 million position during the quarter. The other funds with brand new ALKS positions are Jim Simons’s Renaissance Technologies, Kevin Kotler’s Broadfin Capital, and Brian Ashford-Russell and Tim Woolley’s Polar Capital.

What do corporate executives and insiders think about Alkermes Plc (NASDAQ:ALKS)?

Insider buying is at its handiest when the company in focus has seen transactions within the past six months. Over the latest 180-day time period, Alkermes Plc (NASDAQ:ALKS) has seen zero unique insiders buying, and zero insider sales (see the details of insider trades here).

We’ll also take a look at the relationship between both of these indicators in other stocks similar to Alkermes Plc (NASDAQ:ALKS). These stocks are Delcath Systems, Inc. (NASDAQ:DCTH), Petmed Express Inc (NASDAQ:PETS), Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Elan Corporation, plc (ADR) (NYSE:ELN), and Hospira, Inc. (NYSE:HSP). All of these stocks are in the drug delivery industry and their market caps match ALKS’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!